Q-omics provides the consensus-scored PLXNC1 profile across patient tissues and cancer cell-line models. PLXNC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLXNC1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PLXNC1 protein abundance shows 25,527 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where PLXNC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXNC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXNC1 survival associations across molecular data types. PLXNC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXNC1 RNA expression–survival associations across cancer types. High PLXNC1 expression shows unfavorable associations in UVM and STAD, but favorable associations in HNSC, LUAD, KIRC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLXNC1 RNA expression.
This table summarizes PLXNC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLXNC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXNC1 shows higher tumor expression in KIRC, THCA, HNSC, STAD, LIHC and KIRP. The KIRC box plot shows higher PLXNC1 RNA expression in tumor versus normal tissue (log2 FC = +1.855, t-test p < 0.001).
This table shows molecular features associated with PLXNC1 in patient tissues and cancer cell lines. In patient samples, PLXNC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXNC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
